OTCM
TLIS
Market cap5mUSD
Dec 18, Last price
2.84USD
Name
Talis Biomedical Corp
Chart & Performance
P/E
—
P/S
12.57
EPS
—
Div Yield, %
—
Shrs. gr., 5y
64.60%
Rev. gr., 5y
-29.64%
Revenues
412k
-88.72%
Net income
-62m
L-45.13%
CFO
-53m
L-46.83%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Talis Biomedical Corporation specializes in molecular diagnostics, focusing on the creation of its Talis One system. This system is being developed to address and resolve existing limitations within current point-of-care diagnostic testing technologies for infectious diseases. The company currently provides the Talis One COVID-19 Test System, which is specifically designed for the detection of SARS-CoV-2, the virus responsible for COVID-19. Beyond this, Talis is also developing a range of Talis One assay kits to target respiratory infections, infections related to women's health, and sexually transmitted infections. Its pipeline further includes other diagnostic tests for various respiratory pathogens, such as a panel test capable of identifying influenza A, influenza B, and respiratory syncytial virus. Established in 2013, Talis Biomedical Corporation is headquartered in Menlo Park, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||